Akero Therapeutics Inc (AKRO NASDAQ) stock market data APIs
$51.2813
-0.14(-0.3%)
as of July 3, 2025
Try our APIs with
free plan!
Akero Therapeutics Inc Financial Data Overview
Price chart is built with
Anychart
Akero Therapeutics, Inc. engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21 that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.
Prev. Close
51.2813
Open
51.1411
High
52.1295
Low
50.7618
52 wk Range
21.34-58.4
Market Cap
4 127 M
Shares Outstanding
79 718 K
EPS
-0.9
Beta
-0.16
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Akero Therapeutics Inc data using free add-ons & libraries
Get Akero Therapeutics Inc Fundamental Data
Akero Therapeutics Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -306 329 504
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-08
- EPS/Forecast: -0.9917
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Akero Therapeutics Inc News
New
Madrigal Pharmaceuticals' SWOT analysis: rezdiffra's strong launch propels stock outlook
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) has been making waves in the biotechnology sector with its flagship drug Rezdiffra, a treatment for nonalcoholic steatohepatitis (NASH). With a market capi...
Akero therapeutics CSO Rolph sells $61,914 in shares
Akero Therapeutics, Inc. (NASDAQ:AKRO), a $4.35 billion market cap biotech company whose stock has surged 133% over the past year, reported that Chief Scientific Officer Timothy Rolph sold 1,129 share...
Akero Therapeutics SVP Lamy sells $47k in shares
Akero Therapeutics (NASDAQ:AKRO) Senior Vice President, Commercial Strategy, Patrick Lamy, sold 875 shares of common stock on June 20, 2025, at a price of $54.59, according to a Form 4 filing with the...
Akero Therapeutics (AKRO) CEO Andrew Cheng sells $363k in stock
Andrew Cheng, President and CEO of Akero Therapeutics, Inc. (NASDAQ:AKRO), sold 6,620 shares of common stock on June 18, 2025, according to a Form 4 filing with the Securities and Exchange Commission....
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
